INmune Bio, Inc.
INMB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $55 | $54 | $176 | $104 |
| - Cash | $28 | $33 | $19 | $21 |
| + Debt | $1 | $0 | $0 | $0 |
| Enterprise Value | $28 | $21 | $157 | $84 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | 100% | – |
| EBITDA | -$6 | -$8 | -$10 | -$9 |
| % Margin | – | – | -19,810% | – |
| Net Income | -$6 | -$24 | -$10 | -$9 |
| % Margin | – | – | -19,478% | – |
| EPS Diluted | -0.24 | -1.05 | -0.43 | -0.41 |
| % Growth | 77.1% | -144.2% | -4.9% | – |
| Operating Cash Flow | -$5 | -$7 | -$7 | -$11 |
| Capital Expenditures | -$0 | -$1 | $0 | $0 |
| Free Cash Flow | -$6 | -$8 | -$7 | -$11 |